InvestorsHub Logo
Boards
News
Market Data
Markets
Discover
Discover
Subscribe Login/Register
S&P 500
5,572.85
(
0.10%
)
US TECH 100
19,943.20
(
0.49%
)
Dow Jones
39,344.79
(
-0.08%
)
Brent Oil
85.42
(
-1.26%
)
Bitcoin
56,664.07
(
1.46%
)
Post# of 252525
Next 10
Reply Private New
Public Reply Private Reply New Post
Keep Last Read
Keep Next 10 Report Keyboard Shortcuts
Next 10 Prev Next

ghmm

Send PM Follow Ignore
Followers 50
Posts 6343
Boards Moderated 0
Alias Born 01/22/2006

ghmm

Re: ghmm post# 193936

Wednesday, 08/12/2015 8:26:02 AM

Wednesday, August 12, 2015 8:26:02 AM

Post# of 252525
GLPG / ABBV:

DARWIN 2 24-week monotherapy data in RA confirm previous results
and support best-in-class potential for filgotinib


. ACR50 responses up to 45% as once-daily monotherapy
. DAS28(CRP) low disease activity up to 50%
. Similar efficacy at 100 and 200 mg
. Safety profile in DARWIN 2 consistent with previous filgotinib RA
studies
. These data complete the delivery of the final data package to AbbVie;
triggers the licensing decision period


PR: http://www.glpg.com/files/1114/3922/1696/PR_Darwin2_W24_FINAL.pdf

Webcast: http://edge.media-server.com/m/p/65755a5j

Slides: http://www.glpg.com/files/3614/3937/2304/Webcast_DARWIN_2_week_24_FINAL.pdf

Transcript: http://www.glpg.com/files/8214/3937/2240/DARWIN_2_final_results_transcript.pdf

Public Reply Private Reply New Post
Keep Last Read
Keep Last Read Next 10 Report Keyboard Shortcuts
Next 10 Prev Next

Join the InvestorsHub Community

Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.

Sign Up